Paper: Evaluation of Tumour Exposure following the Administration of an Innovative Cisplatin Dry Powder for Inhalation at Different Dose Levels and Regimens
Nathalie Wauthoz obtained her PHarmD degree in 2006 at Université libre de Bruxelles (ULB). She obtained her PhD degree in Biomedical and Pharmaceutical sciences in 2011 under the supervision of Prof. K. Amighi in Laboratory of Pharmaceutics and Biopharmaceutics (LPB) at ULB. She performed several post-doctoral positions and one of them in the Prof. J.P. Benoit’s Mint unit, INSERM UMR-S 1066 (Angers, France). Since 2017, she is Associate Professor in LPB where she manages and develops the research projects in inhalation field. She had supervised/is supervising 10 PhD students until now.
She has published 47 peer-reviewed papers in internationally recognized journals, 56 abstracts and conference proceedings and is co-inventor on 6 patents. She is also co-founder of the InhaTarget Therapeutics, a spin-off company of the ULB dedicated to the development of innovative dry powders for inhalation (DPIs).
Her research focuses on the development of DPIs to combat different diseases (e.g. lung tumors, infectious diseases, asthma and COPD), and that with different dose (µg to tens of mg) and kind of drugs (e.g. poorly or freely water soluble - conventional or from biotechnologies), with optimal aerodynamic performance, lung retention and eventually increased cell or tumor penetration. Therefore, the formulations were evaluated in vitro on culture cells and in vivo on preclinical models. Nasal formulations for the nose to brain delivery of nucleic acids (e.g. siRNA) or peptide and proteins were also developed and evaluated in vitro on epithelial cell membrane and in vivo by histology and on preclinical models.